Enhertu 100 mg Injection (Trastuzumab Deruxtecan)

 Enhertu (trastuzumab deruxtecan) is a prescription medication used to treat HER2-positive breast cancer. It is given as an intravenous injection (IV) by a healthcare professional.


The dosage of Enhertu depends on the patient's body weight and medical history. It is typically given at a dose of 5.4 mg/kg every three weeks, with a maximum dose of 900 mg per infusion. The duration of treatment varies depending on the response to the medication and the severity of the disease.


Enhertu works by attaching to HER2-positive cancer cells, which are cells that have too much of a protein called human epidermal growth factor receptor 2 (HER2) on their surface. This attachment helps to destroy the cancer cells and slow down the growth of the tumor.


Common side effects of Enhertu include nausea, fatigue, vomiting, decreased appetite, hair loss, and constipation. Enhertu can also cause serious side effects, such as lung problems, heart problems, and infusion-related reactions. Patients should inform their healthcare provider immediately if they experience any of these symptoms or side effects.


It is important to discuss any potential risks and benefits of Enhertu with your healthcare provider before starting treatment. You should also inform your healthcare provider if you have a history of heart or lung problems, as well as any medications you are currently taking.

Comments

Popular posts from this blog

Tofacitinib Tablet 5 mg , Price & side Effects

Carfilzomib Injection 60 mg Price & Side Effects

Enhertu Injection 100 mg Price & Side Effects